Researchers are trying to find out if they can slow the growth of prostate cancer by adding green tea to patients treatment. Researchers are also trying to find out if this could be better or worse than usual care patients get.

This project is a randomized clinical trial (study that randomly assigns participants to one arm to fairly understand outcomes) that aims to assess if information from gene expression classifier (GEC) testing is helpful for both patients and their doctors in the management of care for newly diagnosed prostate cancer patients.

This study will evaluate the safety and tolerability of EG 70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with NMIBC who have failed BCG therapy and have been recommended to have their bladder removed. Giving the study drug inside the bladder is to expose cells in the lining of the bladder, including your cancerous cells, to genes that may cause an immune response inside the bladder and kill the tumor cells.

The rationale for this study is to determine if there is a difference in symptoms or complications among patients undergoing uncomplicated ureteroscopy for stone removal with shorter indwelling stent duration. Curently there are only a few small studies exploring the optimal duration of stent placement after stent placement and no multicenter randomized control trials.

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

A multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with stent omission versus placement of a ureteral stent.

Specific Aim 1: Identify standardized and validated quality of life values among patients undergoing surgical management of BPH Specific Aim 2: Identify the prevalence and severity of financial toxicity among patients undergoing surgical management of BPH Specific Aim 3: Characterize subjective patient priorities regarding procedure characteristics and the impact of these on patient clinical decision making.

Using carefully constructed case vignettes and a survey of oncology providers across a spectrum of settings, we sought to characterize early trends in internalization of the girentuximab PET-CT into care.